CYH33 attenuated cell cycle progression via the p21-Rb-E2F1-SKP2 feedback loop, and co-targeting CDK4/6 enhanced CYH33 activity against ESCC cells and PDXs. This evidence concerns the gene CDKN1A and esophageal squamous cell carcinoma.